The antiparasitic drug ivermectin doesn’t prevent severe disease from Covid-19 any more effectively than symptom management and close observation by medical professionals, according to a study published Friday in the journal JAMA Internal Medicine.
The study enrolled nearly 500 people 50 and older who were at risk of severe Covid-19 because of their age and underlying health. These patients were treated at 20 public hospitals and a quarantine center in Malaysia in 2021.
Half of the patients took a relatively high dose of oral ivermectin for five days, and the other half — the comparison group — received treatment for their symptoms, such as fever-reducing medications. All were monitored for progression of disease.
Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021
Outpatient Visits for COVID-19 and Associated Antibiotic Prescriptions Among Medicare Beneficiaries Aged 65 Years or Older, by Setting, US, April 2020 to April 2021. The volume of COVID-19 visits differed by setting: emergency department, 525 608 (45.8% of all visits); office, 295 983 (25.3%); telehealth, 260 261 (22.3%); and urgent care, 77 268 (6.6%).
Source: Journal of American Medical Association Network